At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Jun 16, 2026 at 08:00 ET
BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 (NLRP3 inhibitor) for cardiovascular risk reduction. Topline data expected H2 2026, a routine operational milestone with no financial or efficacy data disclosed.
- First participant dosed in Phase 2 trial QUELL-CV evaluating BGE-102
- Trial is randomized, double-blind, placebo-controlled, dose-ranging (30/60/90 mg QD) in ~160 participants
- Primary endpoint: percent change from baseline in hsCRP
- Topline data anticipated in second half of 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access